A total of 102 patients were randomized to either mono-therapy with simvastatin ( 40 mg daily ) or triple-therapy with simvastatin ( 40 mg daily ) , extended-release niacin ( 1500 mg daily ) , and ezetimibe ( 10 mg daily ) .